News >

FDA Issues Complete Response Letter for Rituximab Biosimilar

Jason M. Broderick @jasoncology
Published: Thursday, May 03, 2018

The FDA has issued a complete response letter (CRL) to Sandoz (Novartis) regarding a biologics license application (BLA) for the rituximab (Rituxan) biosimilar GP2013.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Publication Bottom Border
Border Publication